Nuvation Bio
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound...
Latest News
18 hours ago · gurufocus.com
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual MeetingNuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual
8 days ago · seekingalpha.com
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks PatientsNuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million, even with new starts flat at about 160. With $663.4 million in cash, NUVB's management believes the company is funded through profitability.
9 days ago · marketbeat.com
What Nuvation Bio (NUVB) Said on Its Q3 Earnings CallNuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across the broader ROS1 treatment market.
12 days ago · seekingalpha.com
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call TranscriptNuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue EstimatesNuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.
12 days ago · prnewswire.com
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateAchieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both first-line and all lines of therapy combined, based on IQVIA claims data FDA approved a supplemental New Drug Application (sNDA) for IBTROZI, updating label to reflect median duration of response of 49.7 months in TKI-naïve ROS1+ NSCLC patients in TRUST-I FDA granted Fast Track Designation to safusidenib for the treatment of IDH1-mutant glioma Cash, cash equivalents, and marketable securities of $663.4 million as of September 30, 2026 Company to host a conference call today at 4:30 p.m. ET NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
15 days ago · prnewswire.com
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual MeetingNuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase 2 results to be presented at SNO includes additional data beyond topline results previously announced in July 2026 NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three posters on ongoing studies of safusidenib, its selective investigational inhibitor of mutant IDH1, will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12–15, 2026, in Philadelphia, PA. Positive topline Phase 2 J201 results were announced in July; additional key data will be featured in the SNO poster.
19 days ago · prnewswire.com
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesNew sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519) study of investigational safusidenib will expand to include study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain. These additional countries extend SIGMA's global footprint beyond the U.S., Australia, China, Canada and Japan, where the study is currently enrolling or will soon begin enrolling.
26 days ago · prnewswire.com
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2026.
2 months ago · prnewswire.com
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung CancerUpdated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months ahead of PDUFA date NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NUVB